Brief Report: Relationship Between Tumor Volume and Clinical Outcomes in Relapsed SCLC.
[INTRODUCTION] For patients with limited-stage SCLC (LS-SCLC), tumor burden is a predictor of clinical outcomes, but there are no known data exploring whether tumor burden is a predictor of clinical o
APA
Lu M, Byrd H, et al. (2025). Brief Report: Relationship Between Tumor Volume and Clinical Outcomes in Relapsed SCLC.. JTO clinical and research reports, 6(12), 100904. https://doi.org/10.1016/j.jtocrr.2025.100904
MLA
Lu M, et al.. "Brief Report: Relationship Between Tumor Volume and Clinical Outcomes in Relapsed SCLC.." JTO clinical and research reports, vol. 6, no. 12, 2025, pp. 100904.
PMID
41256966
Abstract
[INTRODUCTION] For patients with limited-stage SCLC (LS-SCLC), tumor burden is a predictor of clinical outcomes, but there are no known data exploring whether tumor burden is a predictor of clinical outcomes in relapsed SCLC.
[METHODS] In this retrospective correlative study analyzing a cohort of 93 patients with relapsed SCLC, total body tumor volume at time of relapse (TV), progression-free survival (PFS), and overall survival (OS) were calculated and a Cox proportional hazards model was used to evaluate the relationship between TV and PFS and OS.
[RESULTS] A total of 93 patients with relapsed SCLC were analyzed, of whom 70% initially had extensive-stage SCLC (ES-SCLC) and 30% initially had LS-SCLC. Eastern Cooperative Oncology Group performance status and receipt of second-line therapy were significantly associated with OS in a linear fashion ( = 0.002 and = 0.0457, respectively). TV was significantly associated with OS in a nonlinear fashion, even when controlling for Eastern Cooperative Oncology Group performance status, response to initial therapy, chemotherapy-free interval, and receipt of second-line therapy ( = 0.0031).
[CONCLUSIONS] TV was observed to be a predictor of OS in patients with relapsed SCLC. Further studies are needed to evaluate whether initiation of standard systemic therapy at lower TV is able to consistently improve PFS and OS in relapsed SCLC.
[METHODS] In this retrospective correlative study analyzing a cohort of 93 patients with relapsed SCLC, total body tumor volume at time of relapse (TV), progression-free survival (PFS), and overall survival (OS) were calculated and a Cox proportional hazards model was used to evaluate the relationship between TV and PFS and OS.
[RESULTS] A total of 93 patients with relapsed SCLC were analyzed, of whom 70% initially had extensive-stage SCLC (ES-SCLC) and 30% initially had LS-SCLC. Eastern Cooperative Oncology Group performance status and receipt of second-line therapy were significantly associated with OS in a linear fashion ( = 0.002 and = 0.0457, respectively). TV was significantly associated with OS in a nonlinear fashion, even when controlling for Eastern Cooperative Oncology Group performance status, response to initial therapy, chemotherapy-free interval, and receipt of second-line therapy ( = 0.0031).
[CONCLUSIONS] TV was observed to be a predictor of OS in patients with relapsed SCLC. Further studies are needed to evaluate whether initiation of standard systemic therapy at lower TV is able to consistently improve PFS and OS in relapsed SCLC.
같은 제1저자의 인용 많은 논문 (5)
- Primary mediastinal mucormycosis presenting with hoarseness: a case report.
- Study on the role of TIGAR in regulating mitochondrial function and inhibiting pyroptosis of breast cancer cells.
- Discrepancy Between Preoperative CT and Pathological Tumor Diameters in Stage I Lung Adenocarcinoma and Its Association with Postoperative Recurrence.
- Optimization of the fragment binding to hinge region for a potent PIM kinase inhibitor based on N-pyridinyl amide scaffold.
- Development and evaluation of multi-strategy fusion machine learning models for predicting postoperative recurrence in non-small cell lung cancer.